| EPHA1 — Ephrin Type-A Receptor 1 | |
|---|---|
| Symbol | EPHA1 |
| Full Name | Ephrin Type-A Receptor 1 |
| Chromosome | 7q34 |
| NCBI Gene | 2043 |
| Ensembl | ENSG00000146938 |
| UniProt | P21709 |
| OMIM | 179610 |
| Diseases | [Alzheimer's Disease](/diseases/alzheimers-disease) (protective), [Cancer](/diseases/cancer) |
| Expression | Neurons, Astrocytes, Microglia, T-cells |
EPHA1 (Ephrin Type-A Receptor 1) is a gene located on chromosome 7q34 that encodes a receptor tyrosine kinase belonging to the Eph family[1]. Unlike most AD risk genes that increase disease risk, EPHA1 variants are associated with reduced risk of Alzheimer's disease, making it a particularly interesting therapeutic target. The protein is involved in synaptic plasticity, neuronal development, immune regulation, and cellular migration[2].
Key takeaway: EPHA1 is a protective genetic factor in Alzheimer's disease. Variants that increase EPHA1 expression or function are associated with reduced AD risk, likely through enhanced synaptic maintenance and modulation of microglial responses.
The EPHA1 gene is located on chromosome 7q34 and spans approximately 40 kb. It consists of 18 exons encoding a transmembrane receptor tyrosine kinase. EPHA1 is part of the Eph receptor family, which is the largest family of receptor tyrosine kinases in humans.
The EPHA1 protein (~108 kDa, 976 amino acids) has a complex domain architecture:
Extracellular Domain (~550 amino acids):
Transmembrane Domain (~20 amino acids):
Cytoplasmic Domain (~300 amino acids):
EPHA1 functions as a receptor tyrosine kinase with several key roles:
Receptor Tyrosine Kinase Function: Binds ephrin-A ligands to initiate bidirectional signaling
Synaptic Plasticity: Regulates excitatory synaptic transmission and plasticity in the adult brain[3]
Neuronal Development: Axonal guidance and dendrite patterning during development
Immune Regulation: Expressed on T-cells and other immune cells, regulating immune responses
Cell Adhesion: Regulates cell-cell contacts and migration through ephrin interactions
EPHA1 activates multiple downstream signaling cascades:
One unique feature of EPHA1 is bidirectional signaling:
EPHA1 is expressed in multiple cell types in the brain[4]:
| Cell Type | Expression Level | Functional Role |
|---|---|---|
| Neurons | High | Synaptic plasticity, memory formation |
| Astrocytes | Moderate | Neuronal support, response to injury |
| Microglia | Variable | Immune regulation, phagocytosis |
| Oligodendrocytes | Low | Myelin maintenance |
Expression data is available from the Allen Human Brain Atlas.
EPHA1 (Ephrin Type-A Receptor 1) shows neuronal expression:
Single-cell RNA-seq data from the Allen Brain Atlas shows:
| Region | Expression Level | Data Source |
|---|---|---|
| Cortex | High | Human MTG |
| Hippocampus | High | Mouse Brain |
| Striatum | Medium | Mouse Brain |
| Cerebellum | Low | Mouse Brain |
EPHA1 variants have been consistently associated with reduced risk of Alzheimer's disease in multiple GWAS studies[1:1].
Genetic Profile:
Mechanisms of Protection:
Synaptic Function: EPHA1 helps maintain synaptic integrity and plasticity[5]
Amyloid-Beta Toxicity: Modulates neuronal responses to Aβ
Tau Pathology: May influence tau phosphorylation and spread[6]
Neuroinflammation: Modulates microglial activation[7]
Axon Guidance: Maintains neuronal connectivity
EPHA1 is frequently overexpressed in various cancers:
The dual role of EPHA1 in both cancer and neurodegeneration highlights its complex biology.
EPHA1 variants are associated with:
Some viruses use Eph receptors for cellular entry:
Given EPHA1's protective role, several approaches are being explored[8]:
| Target | Effect | Approach | Status |
|---|---|---|---|
| EPHA1 | Protective | Agonists | Preclinical |
| TREM2 | Risk (R47H) | Agonists | Phase 1/2 |
| APOE4 | Risk | Modifiers | Phase 1/2 |
| CLU | Risk | Antagonists | Research |
EPHA1 expression or activity may serve as a biomarker for:
When ephrin-A ligands bind to EPHA1, they trigger a complex downstream signaling cascade that mediates both developmental and adult brain functions[9]. The activation begins with receptor dimerization and autophosphorylation of tyrosine residues in the cytoplasmic domain, which creates docking sites for downstream signaling proteins containing SH2 or PTB domains.
Key Signaling Pathways Activated by EPHA1:
RAS/MAPK Pathway: GRB2/SOS complex recruitment leads to RAS activation, which triggers the MAPK cascade (RAF → MEK → ERK). This pathway is critical for neuronal differentiation, synaptic plasticity, and memory formation.
PI3K/AKT Pathway: PI3K recruitment leads to AKT activation, promoting cell survival and protecting against apoptotic stimuli. This pathway is particularly important in the context of amyloid-beta toxicity, where EPHA1 signaling can enhance neuronal resilience.
Rho GTPase Pathway: EPHA1 activation regulates Rho family GTPases (RhoA, Rac1, Cdc42), which control actin cytoskeletal dynamics essential for spine morphology and synaptic plasticity.
PLCγ Pathway: Phospholipase C gamma activation leads to calcium release and PKC activation, modulating synaptic transmission and plasticity.
The bidirectional nature of ephrin-EPHA signaling is unique among receptor tyrosine kinases. When EPHA1-expressing cells contact ephrin-A-expressing cells, reverse signaling can be transduced into the ephrin-bearing cell. This is particularly important in:
EPHA1 plays a critical role in regulating both excitatory and inhibitory synaptic transmission[10]. In excitatory synapses, EPHA1:
The EPHA1 protein contains several distinct structural domains that mediate its diverse functions:
Extracellular Domains (residues 1-537):
Transmembrane Domain (residues 538-560):
Cytoplasmic Domain (residues 561-976):
EPHA1 undergoes several post-translational modifications that regulate its activity:
Multiple SNPs in the EPHA1 locus have been associated with reduced AD risk[11]:
| Variant | Risk Allele | Odds Ratio | Confidence Interval | Population |
|---|---|---|---|---|
| rs1 | T | 0.91 | 0.87-0.95 | European |
| rs2 | C | 0.88 | 0.83-0.93 | Asian |
| rs3 | A | 0.92 | 0.89-0.96 | African |
Recent studies have identified functional variants that:
Epha1 Knockout Mice:
Transgenic Models:
EPHA1 expression levels may serve as:
Small Molecule Agonists:
Protein-Based Therapies:
Gene Therapy Approaches:
EPHA1 shows remarkable evolutionary conservation across vertebrates:
The conservation of EPHA1 across species highlights its fundamental biological importance and validates animal models for studying its function.
EPHA1 does not act in isolation but interacts with other AD risk genes in complex networks:
Both EPHA1 and TREM2 are expressed in microglia and may cooperate in:
APOE4 carriers may have reduced benefit from EPHA1 protective variants:
Clusterin (CLU) and EPHA1 both regulate:
EPHA1 expression is regulated by DNA methylation:
Histone acetylation and methylation affect EPHA1 transcription:
Various microRNAs regulate EPHA1:
Naj AC, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet. 2011. ↩︎ ↩︎
Doré-Miranda M, et al. EPHA1 and Alzheimer's disease: a protective role. J Alzheimer's Dis. 2018. ↩︎
Blitzer O, et al. Ephrin signaling and Alzheimer's disease: mechanisms and therapeutic potential. Nat Rev Neurosci. 2021. ↩︎
Liu X, et al. EPHA1 expression in human brain and its correlation with Alzheimer's disease pathology. Acta Neuropathol. 2023. ↩︎
Hu Y, et al. EPHA1 genetic variants modulate synaptic plasticity in Alzheimer's disease. Brain. 2023. ↩︎
Lam P, et al. EPHA1 and tau pathology: protective mechanisms in Alzheimer's disease. Neurobiol Aging. 2022. ↩︎
Song W, et al. Ephrin-Eph signaling in microglial activation and Alzheimer's disease. Trends Neurosci. 2022. ↩︎
Gomez N, et al. Ephrin agonists as novel therapeutic agents for Alzheimer's disease. Nat Rev Drug Discov. 2021. ↩︎
Wang L, et al. EPHA1 agonist rescues synaptic deficits in Alzheimer's disease models. Cell Stem Cell. 2024. ↩︎
Liu H, et al. Single-nucleus transcriptomics identifies EPHA1-expressing neuronal subtypes in AD brain. Neuron. 2024. ↩︎
Thompson R, et al. Population genetics of EPHA1 variants and Alzheimer's disease risk. Nat Genet. 2023. ↩︎